Purpose: Gastric and gastroesophageal adenocarcinomas (GEA) represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced GEA is poor. Randomized clinical trials failed to show a significant survival benefit in molecularly unselected patients with advanced GEA treated with anti-EGFR agents. Experimental design: We performed analyses on 4 cohorts: IRCC (570 patients), FMI (9397 patients), COG (214 patients) and INT (206 patients). Preclinical trials were conducted in patient-derived xenografts (PDXs). Results: The analysis of different GEA patient cohorts suggests that EGFR amplification drives aggressive behaviour and poor prognosis. We also observed that EGFR inhibitors are active in patients with EGFR copy number gain and that co-amplification of other receptor tyrosine kinases or KRAS is associated with worse response. Pre-clinical trials performed on EGFR-amplified GEA PDX models revealed that the combination of an EGFR monoclonal antibody and an EGFR tyrosine kinase inhibitor was more effective than each monotherapy and resulted in a deeper and durable response. In a highly EGFR amplified non-responding PDX, where resistance to EGFR drugs was due to inactivation of the TSC2 tumor suppressor, co-treatment with the mTOR inhibitor everolimus restored sensitivity to EGFR inhibition. Conclusions: This study underscores EGFR as a potential therapeutic target in gastric cancer and identifies the combination of an EGFR TKI and a monoclonal antibody as an effective therapeutic approach. Finally, it recognizes mTOR pathway activation as a novel mechanism of primary resistance that can be overcome by the combination of EGFR and mTOR inhibitors.

Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas / S. Corso, F. Pietrantonio, M. Apicella, C. Migliore, D. Conticelli, A. Petrelli, L. D'Errico, S. Durando, D. Moya-Rull, S.E. Bellomo, S. Ughetto, M. Degiuli, R. Reddavid, U. Fumagalli Romario, S. de Pascale, G. Sgroi, E. Rausa, G.L. Baiocchi, S. Molfino, G. de Manzoni, M. Bencivenga, S. Siena, A. Sartore-Bianchi, F. Morano, S. Corallo, M. Prisciandaro, M. Di Bartolomeo, A. Gloghini, S. Marsoni, A. Sottile, A. Sapino, C. Marchiò, A. Dahle-Smith, Z. Miedzybrodzka, J. Lee, S.M. Ali, J.S. Ross, B.M. Alexander, V.A. Miller, R. Petty, A.B. Schrock, S. Giordano. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - (2021). [Epub ahead of print] [10.1158/1078-0432.CCR-20-0121]

Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas

F. Pietrantonio;S. de Pascale;E. Rausa;S. Siena;A. Sartore-Bianchi;M. Prisciandaro;
2021

Abstract

Purpose: Gastric and gastroesophageal adenocarcinomas (GEA) represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced GEA is poor. Randomized clinical trials failed to show a significant survival benefit in molecularly unselected patients with advanced GEA treated with anti-EGFR agents. Experimental design: We performed analyses on 4 cohorts: IRCC (570 patients), FMI (9397 patients), COG (214 patients) and INT (206 patients). Preclinical trials were conducted in patient-derived xenografts (PDXs). Results: The analysis of different GEA patient cohorts suggests that EGFR amplification drives aggressive behaviour and poor prognosis. We also observed that EGFR inhibitors are active in patients with EGFR copy number gain and that co-amplification of other receptor tyrosine kinases or KRAS is associated with worse response. Pre-clinical trials performed on EGFR-amplified GEA PDX models revealed that the combination of an EGFR monoclonal antibody and an EGFR tyrosine kinase inhibitor was more effective than each monotherapy and resulted in a deeper and durable response. In a highly EGFR amplified non-responding PDX, where resistance to EGFR drugs was due to inactivation of the TSC2 tumor suppressor, co-treatment with the mTOR inhibitor everolimus restored sensitivity to EGFR inhibition. Conclusions: This study underscores EGFR as a potential therapeutic target in gastric cancer and identifies the combination of an EGFR TKI and a monoclonal antibody as an effective therapeutic approach. Finally, it recognizes mTOR pathway activation as a novel mechanism of primary resistance that can be overcome by the combination of EGFR and mTOR inhibitors.
EGFR; targeted therapy; gastric and gastroesophageal cancer; drug resistance; mTOR
Settore MED/06 - Oncologia Medica
2021
4-feb-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
1078-0432.CCR-20-0121.full.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 3.19 MB
Formato Adobe PDF
3.19 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/812807
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact